Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Operations (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Cash from Operations for 3 consecutive years, with 32655000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 134.07% to 32655000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10712000.0 through Dec 2025, down 141.1% year-over-year, with the annual reading at 10712000.0 for FY2025, 141.1% down from the prior year.
  • Cash from Operations hit 32655000.0 in Q4 2025 for Immunocore Holdings, down from 4456000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 25964000.0 in Q2 2025 to a low of 32655000.0 in Q4 2025.
  • Historically, Cash from Operations has averaged 1524083.33 across 3 years, with a median of 240000.0 in 2023.
  • Biggest YoY gain for Cash from Operations was 52060.0% in 2024; the steepest drop was 143.52% in 2024.
  • Year by year, Cash from Operations stood at 17733000.0 in 2023, then rose by 21.33% to 13951000.0 in 2024, then plummeted by 134.07% to 32655000.0 in 2025.
  • Business Quant data shows Cash from Operations for IMCR at 32655000.0 in Q4 2025, 4456000.0 in Q3 2025, and 25964000.0 in Q2 2025.